Alnylam Pharmaceuticals (ALNY) PT Raised to $89 at Chardan Capital Markets Following Arrowhead's RNAi Program Discontinuations

November 30, 2016 6:33 AM EST Send to a Friend
Chardan Capital Markets analyst Madhu Kumar reiterated a Buy rating and raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login